Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerKoji Haratani, Kazuhiko Nakagawa, Kaoru Tanaka et al.|JAMA Oncology|2017Cited by 1k
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung CancerKohsuke Isomoto, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2020Cited by 244
B7-H3 Negatively Modulates CTL-Mediated Cancer ImmunityKimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2018Cited by 169
KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling MechanismsShinichiro Suzuki, Kazuhiko Nakagawa, Kimio Yonesaka et al.|Clinical Cancer Research|2021Cited by 105